# EDGAR Filing Document

**Accession Number:** 0001549145
**File Stem:** 0001493152-26-021038
**Filing Date:** 2026-5
**Character Count:** 64611
**Document Hash:** 086ea7090189f8ae6bca5e8dfda6a6a0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-021038.hdr.sgml**: 20260504

**ACCESSION NUMBER**: 0001493152-26-021038

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 60

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260504

**DATE AS OF CHANGE**: 20260504

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BLUE BIOFUELS, INC.
- **CENTRAL INDEX KEY:** 0001549145
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL ORGANIC CHEMICALS [2860]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 454944960
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54942
- **FILM NUMBER:** 26935772

**BUSINESS ADDRESS:**
- **STREET 1:** 3710 BUCKEYE ST
- **STREET 2:** SUITE 120
- **CITY:** PALM BEACH GARDENS
- **STATE:** FL
- **ZIP:** 33401
- **BUSINESS PHONE:** (888)607-3555

**MAIL ADDRESS:**
- **STREET 1:** 3710 BUCKEYE ST
- **STREET 2:** SUITE 120
- **CITY:** PALM BEACH GARDENS
- **STATE:** FL
- **ZIP:** 33401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLIANCE BIOENERGY PLUS, INC.
- **DATE OF NAME CHANGE:** 20141204

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alliance Media Group Holdings, Inc.
- **DATE OF NAME CHANGE:** 20120504

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Quarter ended March 31, 2026

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission File Number: 000-54942

**<u>BLUE BIOFUELS, INC.</u>**

(Exact name of small Business Issuer as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **45-4944960** |
| (State or other jurisdiction | (IRS Employer |
| of incorporation or organization) | Identification No.) |

---

---

| | |
|:---|:---|
| **3710 Buckeye Street, Suite 120**<br>**Palm Beach Gardens, FL** | **33410** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(888) 607-3555</u>**

n/a

Former name or former address if changed since last report

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock par value $0.001 | BIOF | OTCQB |

---

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒ Emerging Growth Company ☐ <br> Smaller reporting company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

State the number of shares outstanding of the registrant's $.001 par value common stock as of the close of business on the latest practicable date (April 22, 2026): 320,948,112.

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  |  | Page |
|  | [PART I—FINANCIAL INFORMATION](#a_001) | 3 |
| ITEM 1. | [Condensed Financial Statements (unaudited)](#a_002) | 4 |
| ITEM 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_008) | 16 |
| ITEM 3. | [Quantitative and Qualitative Disclosures About Market Risk](#a_009) | 19 |
| ITEM 4. | [Controls and Procedures](#a_010) | 19 |
|  | [PART II—OTHER INFORMATION](#a_011) | 20 |
| ITEM 1. | [Legal Proceedings](#a_012) | 20 |
| ITEM 1A. | [Risk Factors](#a_013) | 20 |
| ITEM 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#a_014) | 20 |
| ITEM 3. | [Defaults Upon Senior Securities](#a_015) | 21 |
| ITEM 4. | [Mine Safety Disclosures](#a_016) | 21 |
| ITEM 5. | [Other Information](#a_017) | 21 |
| ITEM 6. | [Exhibits](#a_018) | 21 |
|  | [Signatures](#a_019) | 22 |

---

**PART I – FINANCIAL INFORMATION**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **Index to Financial Statements** | **Page** |
| [Condensed Balance Sheets as of March 31, 2026, and December 31, 2025 (unaudited)](#a_003) | 4 |
| [Condensed Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#a_004) | 5 |
| [Condensed Statements of Stockholders' Deficit for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#a_005) | 6 |
| [Condensed Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (unaudited)](#a_006) | 7 |
| [Notes to Condensed Financial Statements (unaudited)](#a_007) | 8 |

---

**Blue Biofuels, Inc.**

**Financial Statements**

**UNAUDITED FINANCIAL STATEMENTS**

**OF**

**BLUE BIOFUELS, INC.**

**Blue Biofuels, Inc.**

**CONDENSED BALANCE SHEETS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| **ASSETS** |  |  |
| **Current Assets** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and Cash Equivalents | $8665 | $65200 |
| &nbsp;&nbsp;&nbsp;Prepaid Expenses | 11551 | 11551 |
| **TOTAL CURRENT ASSETS** | **20216** | **76751** |
| **Other Assets** |  |  |
| &nbsp;&nbsp;&nbsp;Property and Equipment, net of accumulated depreciation and amortization of $512,877 and $482,578 at March 31, 2026 and December 31, 2025, respectively | 524810 | 555109 |
| &nbsp;&nbsp;&nbsp;Deposits | 90276 | 80276 |
| &nbsp;&nbsp;&nbsp;Right of Use Assets, net of accumulated amortization | 345587 | 365414 |
| &nbsp;&nbsp;&nbsp;Patents and Trademarks, net of accumulated amortization | 328751 | 329829 |
| **TOTAL OTHER ASSETS** | **1289424** | **1330628** |
| **TOTAL ASSETS** | $**1309640** | $**1407379** |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts Payable | $154835 | $154897 |
| &nbsp;&nbsp;&nbsp;Accounts Payable - Related Party | 48570 | 48570 |
| &nbsp;&nbsp;&nbsp;Deferred Wages and Directors' Fees - Related party | 2681060 | 2525135 |
| &nbsp;&nbsp;&nbsp;Right of Use Lease Liability - Current | 82166 | 79316 |
| &nbsp;&nbsp;&nbsp;Interest Payable - Related Party | 152484 | 176484 |
| **TOTAL CURRENT LIABILITIES** | **3119115** | **2984402** |
| **Long term liabilities** |  |  |
| Right of Use Lease Liability, Long Term | 271621 | 293430 |
| Notes Payable — Related Party | 1345000 | 1325000 |
| Convertible Notes Payable — Related Party | 190000 | 190000 |
| Legacy Notes Payable | 320630 | 320630 |
| **TOTAL LONG TERM LIABILITIES** | **2127251** | **2129060** |
| **TOTAL LIABILITIES** | **5246366** | **5113462** |
| **COMMITMENTS AND CONTINGENCIES (NOTES 8 AND 9)** |  |  |
| **STOCKHOLDERS' DEFICIT** |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Common stock; $0.001 par value; 1,000,000,000 shares authorized; 320,948,112 and 317,872,112 issued and outstanding at March 31, 2026 and December 31, 2025, respectively. | 320948 | 317872 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 56536489 | 56106407 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (60794163) | (60130362) |
| **TOTAL STOCKHOLDERS' DEFICIT** | $**(3936726)** | $**(3706083)** |
| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $**1309640** | $**1407379** |

---

*The accompanying notes to the Condensed Financial Statements are an integral part of these statements.*

**Blue Biofuels, Inc**

**CONDENSED STATEMENTS OF OPERATIONS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31** | **March 31** |
|  | **2026** | **2025** |
| **Revenue** | $- | $- |
| **Operating expense:** |  |  |
| &nbsp;&nbsp;&nbsp;General and administrative | 274585 | 338098 |
| &nbsp;&nbsp;&nbsp;Research and development | 384913 | 350707 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 659498 | 688805 |
| **Loss from operations:** | **(659498)** | **(688805)** |
| **Other (income) expense:** |  |  |
| &nbsp;&nbsp;&nbsp; Government grant income |  | (444970) |
| &nbsp;&nbsp;&nbsp;Interest expense - related party | 4303 |  |
| &nbsp;&nbsp;&nbsp;Other (income) expense | - | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other (income) expense | 4303 | (444972) |
| **Income (Loss) before provisions for income taxes** | $**(663801)** | $**(243833)** |
| &nbsp;&nbsp;&nbsp;Provisions for income taxes | **-** | **-** |
| **Net Income (Loss)** | $**(663801)** | $**(243833)** |
| **Net income (loss) per share - basic and diluted** | $**(0.002)** | $**(0.001)** |
| **Weighted average common shares outstanding** |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 319225834 | 308459719 |
| &nbsp;&nbsp;&nbsp;Diluted | 319225834 | 308459719 |

---

*The accompanying notes to the Condensed Financial Statements are an integral part of these statements.*

**Blue Biofuels, Inc.**

**CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | | | |
|  | **Shares** | **Amount** | Additional<br> Paid-in<br>**Capital** | Accumulated<br>**Deficit** | Total Stockholder's<br>**Deficit** |
| **Balance as of December 31, 2025** | **317872112** | $**317872** | $**56106407** | $**(60130362)** | $**(3706083)** |
| Issuance of common stock for services | 10000 | $10 | $1240 |  | $1250 |
| Issuance of 30,000 warrants for interest |  |  | 4303 |  | 4303 |
| Issuance of common stock and warrants for cash in Private Placement | 1816000 | $1816 | 225184 |  | $227000 |
| Issuance of common stock for the exercise of warrants | 1250000 | 1250 | 123750 |  | 125000 |
| Stock based compensation recognized under the employee, director plan |  |  | 75605 |  | 75605 |
| Net Income (Loss) |  |  |  | (663801) | (663801) |
| **Balance as of March 31, 2026** | **320948112** | $**320948** | $**56536489** | $**(60794163)** | $**(3936726)** |
| **Balance as of December 31, 2024** | **307960508** | $**307961** | $**54101897** | $**(57255761)** | $**(2845903)** |
| Employee director stock options exercised on a cashless basis | 44000 | 44 | (44) |  |  |
| Issuance of common stock and warrants on the conversion of notes | 625000 | 625 | 49375 |  | 50000 |
| Stock based compensation recognized under the employee, director plan |  |  | 88165 |  | 88165 |
| Net Income (Loss) |  |  |  | (243833) | (243833) |
| **Balance as of March 31, 2025** | **308629508** | $**308630** | $**54239393** | $**(57499594)** | $**(2951571)** |

---

*The accompanying notes to the Condensed Financial Statements are an integral part of these statements.*

**Blue Biofuels, Inc.**

**CONDENSED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31** | **March 31** |
|  | **2026** | **2025** |
| **Cash flows from operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;**Net Income (Loss)** | $**(663801)** | $**(243833)** |
| &nbsp;&nbsp;&nbsp;**Reconciliation of net loss to net cash used in operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 31377 | 29926 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation | 76855 | 88165 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of warrants for interest expense | 4303 |  |
| &nbsp;&nbsp;&nbsp;**Changes in operating assets and liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (62) | 12609 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred wages and directors fees -- related party | 155925 | 124861 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest payable - related party | (24000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right of use lease | 868 | 1688 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) operating activities** | **(418535)** | **13416** |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment |  | (104630) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of deposit on property | (10000) | (50000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to patent and trademark costs | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) investing activities** | **(10000)** | **(154630)** |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock and warrants | 227000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the exercise of warrants | 125000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the issuance of notes payable -- RP | 20000 | 100000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | **372000** | **100000** |
| **Net increase (decrease) in cash and cash equivalents** | **(56535)** | **(41214)** |
| **Cash and cash equivalent at beginning of the period** | **65200** | **48797** |
| **Cash and cash equivalent at end of the period** | $**8665** | $**7583** |
| **Non-cash financing and investing activities** |  |  |
| &nbsp;&nbsp;&nbsp; Issuance of common stock and warrants on the conversion of notes payable | $- | $50000 |

---

*The accompanying notes to the Condensed Financial Statements are an integral part of these statements.*

**Blue Biofuels, Inc.**

**NOTES TO CONDENSED FINANCIAL STATEMENTS**

**(Unaudited)**

**NOTE 1 – ORGANIZATION**

Blue Biofuels, Inc., was incorporated in Nevada on March 28, 2012, as Alliance Media Group Holdings, Inc. Since December 2013, Blue Biofuels, Inc. (the "Company") has been a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

**NOTE 2 – GOING CONCERN**

The accompanying condensed financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of March 31, 2026, the Company has incurred accumulated losses of $60,794,163. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

Management believes that the Company's future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company's inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence.

**NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation*

The condensed financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The condensed financial statements do not include all disclosures required of annual financial statements and, accordingly, should be read in conjunction with our financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Operating results for the three months ended March 31, 2026, may not be indicative of full year 2026 results.

In management's opinion, the accompanying condensed financial statements contain all adjustments necessary for a fair statement of our financial position as of March 31, 2026, and our results of operations, changes in stockholders' deficit and cash flows for the three months ended March 31, 2026 and 2025.

*Net Income (Loss) per Common Share:*

Basic net earnings per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted earnings per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as common stock that potentially could be issued upon the conversion of convertible notes or upon the exercise of outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method.

For the three months ended March 31, 2026 and 2025, due to net losses, all potential dilutive securities are antidilutive. There are a total of 87,321,907 common shares that would be issued if all warrants, vested options, and convertible notes were exercised.

*Grant Income*

Government grants income is recognized in earnings on a systematic basis in a manner that mirrors the manner in which the Company recognizes the underlying costs for which the grant is intended to compensate. A grant receivable is recognized for expenses or losses already incurred but for which grant funding has not yet been received. Grant funding received in excess of expenses or losses incurred is recognized as deferred revenue.

The Company has adopted the disclosure requirements of Accounting Standards Codification ("ASC") 832 Government Assistance.

*Recent Accounting Pronouncements*

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company's annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the ASU to determine its impact on our consolidated financial statements and disclosures.

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company's accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

**NOTE 4 – PROPERTY AND EQUIPMENT**

---

| | | | |
|:---|:---|:---|:---|
| **PROPERTY AND EQUIPMENT** | **Life** | **March 31, 2026** | **December 31, 2025** |
| Building and Improvements | 15 | $9370 | $9370 |
| Construction and Engineering | 10 | 171817 | 171817 |
| Machinery and Equipment | 10 | 831079 | 831079 |
| Furniture and Fixtures | 5 | 13596 | 13596 |
| Computer Equipment | 3 | 11825 | 11825 |
|  |  | 1037687 | 1037687 |
| &nbsp;&nbsp;&nbsp;Less Accumulated Depreciation |  | $(512877) | $(482578) |
| &nbsp;&nbsp;&nbsp;Property and Equipment |  | $524810 | $555109 |

---

Total depreciation expense was $30,299 and $29,926 for the three months ended March 31, 2026 and 2025, respectively.

**NOTE 5 – PATENTS AND TRADEMARKS**

The Company has obtained three patents and has applied for six more patents on its technology, and has also applied for international patents. The Company has obtained one trademark and has four more pending. The following is a summary of the Company's patents and trademarks at March 31, 2026 and December 31, 2025:

---

| | | |
|:---|:---|:---|
|  | March 31, 2026 | December 31, 2025 |
| Trademarks issued | $8340 | $8340 |
| Patents issued | 86259 | 86259 |
| Patents and trademarks issued, at cost | 94599 | 94599 |
| Accumulated amortization | (26239) | (25161) |
| Net balance of issued patents and trademarks | $68360 | $69438 |
| Patents and trademarks pending | 260391 | 260391 |
| &nbsp;&nbsp;&nbsp;TOTAL PATENTS AND TRADEMARKS | $328751 | $329829 |

---

Amortization expenses for patents and trademarks for the three months ended March 31, 2026, and 2025 were $1,078 and $0, respectively. Estimated amortization expense for the years subsequent to March 31, 2026, is as follows:

---

| | |
|:---|:---|
| Year ending December 31, |  |
| 2026 remaining | $3235 |
| 2027 | 4313 |
| 2028 | 4313 |
| 2029 | 4313 |
| 2030 | 4313 |
| Thereafter | 39533 |
| &nbsp;&nbsp;&nbsp;TOTAL | $60020 |

---

**NOTE 6 – DEBT**

*Notes Payable – Related Party*

From 2023 to 2025, the Company borrowed a total of $1,325,000 from board member Chris Kneppers. The notes are now payable on the earliest of the date on which the Company (1) uplists to the Nasdaq or NYSE; (2) receives $5 million in equity financing; or (3) begins generating revenue from its first facility. During the three month period ended March 31, 2026, the Company borrowed an additional $20,000 from Mr. Kneppers with the same terms. The total debt due as of March 31, 2026, is $1,345,000. In lieu of interest, the Company will pay Mr. Kneppers 100% of the outstanding loan balance due him contingent upon the financing of the first plant. All interest and loan amounts automatically come due upon a change of control of the Company or if the Company files for bankruptcy under Chapter 11 or Chapter 7. At March 31, 2026 and December 31, 2025, accrued interest payable to Mr. Kneppers is $46,651, and $46,651, respectively.

*Convertible Notes Payable – Related Party*

In June and November 2023, the Company entered two long-term convertible notes with board member Edmund Burke with principal amounts of $25,000 and $15,000, respectively, to be repaid when the Company receives an equity investment of at least $3 million. The notes may convert into common stock at $0.13/share at the option of the holder for a total of 307,692 shares. Until repayment, the note agreement requires the Company to issue to Mr. Burke 80,000 warrants having a strike price of $0.15 and an expiration of 5 years every twelve months in lieu of interest. During the quarter ended March 31, 2026 and 2025, 30,000 and 0 warrants with a fair value of $4,303 and $0,respectively, were issued to Mr. Burke (see Note 7). The fair value of these warrants is included in interest expense – related parties on the statement of operations.

In April 2023, the Company entered a separate long-term convertible note with board member Mr. Burke, with a principal balance of $150,000, to be repaid when the Company receives an equity investment of at least $1.5 million. The notes may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares. Until repayment, the note agreement requires the Company to issue to Mr. Burke 100,000 warrants having a strike price of $0.15 and an expiration of 5 years every six months in lieu of interest. During the three months ended March 31, 2026 and March 31, 2025, 0 and 0 warrants with a fair value of $0 and $0, respectively, were issued to Mr. Burke (see Note 7). The fair value of these warrants is included in interest expense – related parties on the statement of operations.

Pursuant to the Company's Chapter 11 Plan of Reorganization confirmed on September 18, 2019, the Company restructured several outstanding notes payable and convertible debentures into fixed settlement obligations. Under the terms of the confirmed Plan, the original terms, interest rates, and conversion features were terminated in exchange for a combined settlement of $320,630, payable solely out of the Company's future gross revenues or a percentage thereof. As of March 31, 2026 and December 31, 2025, the remaining aggregate balance of these obligations is $320,630.

A summary of all Notes that remain including those indicated in the Notes above is as follows:

---

| | | |
|:---|:---|:---|
| **Notes Payable** | **March 31, 2026** | **December 31, 2025** |
| Current Convertible Notes — Other | $- | $- |
| Long Term Convertible Notes Payable – Related Party | 190000 | 190000 |
| Long-Term Notes Payable – Related Party | 1345000 | 1325000 |
| Long Term Notes Payable from future revenue | 320630 | 320630 |
| **TOTAL NOTES** | $**1855630** | $**1835630** |

---

As of March 31, 2026, none of the $1,855,630 outstanding notes payable is due at a specific point in time. $320,630 will be paid from future gross revenues.

At March 31, 2026, there are $190,000 in convertible notes that, if converted, would convert into 1,461,538 shares.

**NOTE 7 – STOCKHOLDERS' EQUITY**

During the three months ended March 31, 2026, and 2025, the Company issued an aggregate of 10,000 and 0 shares, respectively, of its common stock for services with a fair value based on the trading price of the Company's stock on the date of issuance of $1,250 and $0, respectively.

During the three months ended March 31, 2026, in connection with the exercise of warrants, the Company issued 1,250,000 shares of its common stock for $125,000.

During the three months ended March 31, 2026, the Company issued 1,816,000 shares and warrants in a private placement for proceeds of $227,000.

<u>Warrants</u>:

During the three-month period ended March 31, 2026 and 2025, the Company issued 30,000 and 0 warrants for interest with a fair value of $4,303 and $0, respectively.

A summary of warrant activity for the year ended December 31, 2025 and three months ended March 31, 2026 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Number of<br> Warrants** | **Weighted Average<br> Exercise Price** |
| Balance, December 31, 2024 | 27446495 | $0.21 |
| Issued in connection with: |  |  |
| &nbsp;&nbsp;&nbsp;Common stock units sold for cash | 6830000 | 0.16 |
| &nbsp;&nbsp;&nbsp;Services | 266000 | 0.12 |
| &nbsp;&nbsp;&nbsp;Debt-related interest | 250000 | 0.15 |
| &nbsp;&nbsp;&nbsp;Debt conversion | 625000 | 0.10 |
| Expired | (500000) | 0.20 |
| Exercised | (750000) | 0.09 |
| Balance, December 31, 2025 | 34167495 | 0.20 |
| Issued in connection with: |  |  |
| &nbsp;&nbsp;&nbsp; Common stock units sold for cash | 1816000 | 0.18 |
| &nbsp;&nbsp;&nbsp; Debt-related interest | 30000 | 0.15 |
| Exercised | (1250000) | 0.10 |
| Expired | - | - |
| Balance, March 31, 2026 | 34763495 | 0.20 |

---

Warrants outstanding at March 31, 2026 have a weighted average exercise price of $0.20 and a weighted average remaining term of 2.7 years.

Stock Options:

During the three-month period ended March 31, 2026 and 2025, the Company recognized $75,605 and $88,165 of stock based compensation, respectively, under the employee, director plan. Of this amount, $288 (2025: $33,709) was classified as general and administrative expense and $75,317 (2025: $54,456) was classified as research and development expenses.

A summary of option activity for the year ended December 31, 2025, and three months ended March 31, 2026, is as follows:

---

| | | |
|:---|:---|:---|
|  | **Number of**<br> **Options** | **Weighted Average**<br> **Exercise Price** |
| Balance, December 31, 2024 | 88971571 | $0.13 |
| Options granted | 12774470 | 0.12 |
| Options expired | (3658335) | 0.15 |
| Options exercised | (650000) | 0.06 |
| Balance, December 31, 2025 | 97437706 | 0.13 |
| Options granted |  |  |
| Options expired | (10000) | 0.15 |
| Options exercised | - | - |
| Balance, March 31, 2026 | 97427706 | 0.13 |
| Vested, March 31, 2026 | 50596874 | 0.13 |

---

The weighted average remaining life of outstanding and vested options is 6.2 years and 5.9 years, respectively. At March 31, 2026, outstanding vested options had an intrinsic value of $984,775, and the total intrinsic value of all options is $1,921,093.

At March 31, 2026, remaining compensation to be recognized as future vesting of stock options is approximately $5.2 million of which approximately $0.2 million will vest in 2026, $0.1 in subsequent years, and approximately $4.9 million will vest upon the probability of achieving performance milestone criteria.

Black Scholes Model Variables:

The fair value associated with warrants and options issued during the three months ended March 31, 2026, were valued on the date of issuance or modification.

The following assumptions were used in calculations of the Black-Scholes option pricing models for option and warrant-based stock compensation issued in the quarters ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
|  | March 31, 2026 | March 31, 2025 |
| Exercise price | $0.15 | $0.11 |
| Risk-free interest rate | 3.74% | 4.54% |
| Expected term (in years) | 5.0 | 10.0 |
| Expected share price volatility | 102.26% | 109.69% |
| Expected dividend yield | 0.0% - 0.0% | 0.0% - 0.0% |

---

**NOTE 8 - COMMITMENTS AND CONTINGENCIES**

***Litigation***

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.

***Leases***

The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use ("ROU") assets and operating lease liabilities in the Company's condensed balance sheet. The new lease has a term of five years, expires on October 31, 2029, and has escalating monthly payments range from $9,100 to $10,242. At inception, the lease was classified as an operating lease and the Company recorded a ROU lease asset and liability of $452,132 and $452,132, respectively, at a discount rate of 10%. Rent expense for the three months ending March 31, 2026, and 2025 were $62,146 and $57,579, respectively, which is expensed as part of G&A in the statement of operations.

At March 31, 2026, minimum lease payments to be paid by the Company are as follows:

---

| | |
|:---|:---|
| Remainder of 2026 | $84923 |
| 2027 | 116434 |
| 2028 | 119928 |
| 2029 | 102426 |
| Total lease payments | 423711 |
| Less imputed interest | (69924) |
| Present value of lease liabilities | 353787 |
| Current portion | (82166) |
| Long term portion | $271621 |

---

**NOTE 9 – RELATED PARTY TRANSACTIONS**

Related Party transactions with the Company are as follows:

1) Short-term notes payable, convertible notes, and legacy liabilities issued to related parties are described in NOTE 6.

2) A board resolution was passed on February 13, 2020 that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they receive less than full salaries.

3) During 2024, the board of directors approved an increase in salaries to two officers of the Company retroactive to August 1, 2023, in light of the fact that they are not receiving payments of salaries on a consistent basis. CEO Ben Slager is to receive annual salary of $525,000 and CFO Anthony Santelli $325,000.

4) In June 2024, the board of directors approved a partial anti-dilution compensation for CEO Ben Slager, CFO Anthony Santelli, and Director Chris Kneppers to be paid in restricted stock units and options of 4%, 3%, and 3%, respectively, of the equity and warrants granted to investors on the next $50 million in equity raised into the Company or its subsidiaries. This is compensation for their deferring salary or lending funds to the Company until such raise(s) is affected. These restricted share units will be issued as the Company raises capital through sale of its common stock. As of March 31, 2026, Ben Slager is to be issued 419,440 RSUs and options with an exercise price ranging from 15 to 18 cents and expiring five years from issuance, and both Anthony Santelli and Chris Kneppers are each to be issued 314,580 RSUs and 314,580 options with the same terms. None of the RSUs nor options have been issued as of March 31, 2026.

5) As of April 1, 2024, the board of directors approved ceasing accruing interest on back pay due to officers and on directors fees. In lieu of interest, the Company will pay an additional $25,000 to each director contingent upon the financing of the first plant or the successful uplisting to the NYSE or Nasdaq. Similarly, a performance bonus equal to 100% of the outstanding back pay balance due to Officers Ben Slager and Anthony Santelli shall be paid contingent upon the financing of the first plant. These amounts automatically come due upon a Change of Control or if the Company files for bankruptcy under Chapter 11 or Chapter 7.

6) As of August 28, 2024, each Director that is not an Officer shall receive 3.5% in cash and 3.5% in warrants for any investor first introduced to the Company by the Director. The warrants shall either be at the same price as any warrants being offered in the raise, or, if there are no warrants in the raise, then at the closing market price on the date in which the funds are received. All warrants will have a 5-year expiration from the date of the investment. No such cash/warrants have been earned to date.

7) On December 15, 2025, the Board of Directors approved of a $500,000 bonus for Ben Slager for having met the milestone of being able to produce over 500 lbs of sugar in an 8-hour day, an offer originally made on March 12, 2021, as an incentive to upscale and commercialize the Company's patented CTS system. This amount is accrued in Deferred Wages and Directors' Fees – Related party as of March 31, 2026 and December 31, 2025.

**NOTE 10 – GRANT INCOME**

In September 2024, the Company was awarded a Small Business Innovation Research ("SBIR") grant by the U.S. Department of Energy (DOE) in the amount of $1.15 million to be received subject to meeting certain terms and conditions. The purpose of the grant is to support the further development of the Company's patented CTS process and to bring it to the point of being commercially ready. Accounting for this DOE grant does not fall under Accounting Standard Codification 606, *Revenue from Contracts with Customers*, as the DOE does not meet the definition of a customer under this standard. During the year ended December 31, 2025, $865,000 was recognized as grant income for this grant.

During the three month periods ended March 31, 2025, $444,970 was recognized as grant income for this grant. None was recognized during the quarter ended March 31, 2026, as there is no additional grant money from this grant for 2026.

**NOTE 11 – SUBSEQUENT EVENTS**

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

The Company received $50,000 from a board member in exchange for a note with the same terms as previous notes. See Note 6, Notes Payable Related Party, above.

The Company received $100,000 from an unrelated party in exchange for a note. The note has a $10,000 origination fee and is payable in 12 months. At the option of the holder, instead of the origination fee, the Note may be converted into shares at 12.5 cents per share plus a warrant with a strike price of 18 cents and a 5-year expiration.

The Company issued 200,000 warrants for annual interest on a $150,000 note to a board member. See Note 6 Convertible Notes Payable, above.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Forward-Looking Statements**

This quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words "believe," "anticipate," "expect," "estimate," "intend", "plan" and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management's current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of "penny stocks"; and other risks and uncertainties. Some of those risks and uncertainties include the risk factors set forth in this report and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this financial statement identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement.

**Business Overview**

Blue Biofuels, Inc., was incorporated in Nevada on March 28, 2012, as Alliance Media Group Holdings, Inc. Since December 2013, Blue Biofuels, Inc. (the "Company") has been a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

In early 2018, our chief executive officer ("CEO") Ben Slager invented a new technology system referred to as Cellulose-to-Sugar or CTS, and, to date, the Company filed, and received, three patents for this technology. The CTS process is a continuous mechanical/chemical process for converting cellulose material into sugar and lignin. Three additional patent applications have been filed and are pending.

The CTS system converts plant-based feedstock into one primary product, soluble sugars, which can be further processed into cellulosic ethanol and other biofuels like jet fuel, bio-gasoline, and potentially into bio chemicals.

In 2025, the Company finalized the upscaling, testing, and optimizing of the pilot plant and is in the process of finalizing design and operational parameters for cost estimates of a full-scale commercial volume system.

In addition, the Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF) and other renewable biofuels including bio-gasoline.

**Plan of Operation**

The total process from cellulosic feedstock to SAF consists basically of three steps:

1) Conversion from feedstock to fermentable cellulosic sugars (CTS) <br> 2) Ferment the cellulosic sugars into cellulosic ethanol. <br> 3) Covert the ethanol into SAF and related products. This third step happens with the Vertimass technology which the Company has licensed.

In January 2024, the Company formed a 50-50 joint venture partnership with Vertimass called VertiBlue Fuels, LLC, that has the mission to build an ethanol-to-SAF facility in Florida with the initial goal to produce around 10-25 million gallons of Sustainable Aviation Fuel (SAF), and then expand SAF production to approximately 70 million gallon per year. VertiBlue Fuels plans to initially convert sugarcane ethanol, and then, as soon as the Company's first CTS technology factory is finalized, switch to cellulosic ethanol. The plan is to build commercial CTS and ethanol facilities on the front-end of ethanol-to-SAF facilities to produce cellulosic SAF and generate the large D7 RIN and other government credits. Commencing commercial production will require project financing.

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the CTS technology or forming joint ventures with foreign domestic partners to build plants.

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

**Capital Formation**

From January 1, 2026, through the date of filing, the Company issued an aggregate of 10,000 shares of its common stock for services valued at $1,250.

From January 1, 2026, through the date of filing, the Company issued an aggregate of 230,000 warrants for interest on notes to a related party.

From January 1, 2026, through the date of filing, the Company issued an aggregate of 1,816,000 shares and warrants for $227,000 in a private placement.

From January 1, 2026, through the date of filing, the Company issued an aggregate of 1,250,000 shares for the exercise of warrants and received proceeds of $125,000.

From January 1, 2026, through the date of filing, 3,147,550 options vested. During the three months ended March 31, 2026, the Company recognized stock-based compensation of $75,605 in connection with the expensing of unvested options.

From January 1, 2026, through the date of filing, 10,000 vested options expired.

**Going Concern**

The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further capital. As of March 31, 2026, the Company had a working capital deficit of $3,098,898 and had incurred accumulated losses of $60,794,163 since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, there is substantial doubt about the Company's ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company's ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses.

**Results of Operations**

***Comparison of the three month period ended March 31, 2026 to March 31, 2025***

For the three months ended March 31, 2026, the Company recognized $0 in revenue as opposed to $0 in 2025.

For the three months ended March 31, 2026, the Company's general and administrative expenses decreased by $63,513 to $274,585 from $338,098 in 2025. This decrease is primarily the result of $56,199 in consulting expenses in 2025 versus $20,744 in 2026.

Interest expense increased in the quarter ended March 31, 2026 by $4,303 from $0 in 2025.

Research and development (R&D) costs for the quarter ended March 31, 2026, were $384,913, an increase of $34,206 from $350,707 in 2025. The increase in R&D expenses is primarily the result of equity-based compensation of $75,317 in 2026 versus $54,456 in 2025.

**Liquidity and Capital Resources**

Liquidity

As of March 31, 2026, the Company had $8,665 in cash and cash equivalents, and total stockholders' deficit on March 31, 2026, was $3,936,726. As of December 31, 2025, the Company had $65,200 in cash and cash equivalents, and total stockholders' deficit at December 31, 2025, was $3,706,083. Total debt, including convertible notes, accounts payable and other notes payable at March 31, 2026, together with interest payable thereon and legacy liabilities, was $5,246,366 an increase of $132,904 from December 31, 2025, where it stood at $5,113,462. This increase is primarily attributable to an increase in deferred wages of $155,925.

During the three months ended March 31, 2026, the Company's net cash used in operating activities was $418,535 compared to net cash provided by operating activities of $13,416 in the three months ending March 31, 2025. This is primarily attributed to a higher net loss in 2026 due to grant income in 2025.

During the three months ended March 31, 2026, the Company generated an aggregate of $372,000 versus $100,000 through its financing activities in the three months ended March 31, 2025, which is an increase of $272,000. This increase from the prior year can primarily be attributed to net proceeds of $227,000 in a private placement and $125,000 from the exercise of warrants versus $100,000 for the issuance of notes payable in 2025 versus $20,000 in 2026.

Capital Resources

At this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate revenue or obtain additional financing for current and future operations. The Company anticipates needing additional funds for G&A expenses and will seek project financing for a commercial ethanol to SAF facility in addition to funds needed to complete the commercialization of its CTS system. There is no guarantee that the Company will achieve all of the additional funding that is needed.

As of the date of this filing, in 2026 the Company has raised $352,000 through the issuance of shares and $170,000 from the issuance of notes. The Company previously raised $17,974,375 in shares and $2,245,916 through converted notes and $1,515,000 in debt or convertible notes since inception. However, there is no guarantee that the Company will be able to raise any additional capital on terms acceptable to the Company.

The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations.

**Equity**

As of March 31, 2026, shareholders' deficit was $3,936,726.

There were 320,948,112 shares of common stock issued and outstanding as of March 31, 2026.

There were no preferred shares outstanding.

The Company has paid no dividends.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

**ITEM 4. CONTROLS AND PROCEDURES**

***Evaluation of Disclosure Controls and Procedures***

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of March 31, 2026. Based upon, and as of the date of this evaluation, our chief executive officer and chief financial officer determined that our disclosure controls and procedures were effective.

***Changes in Internal Control over Financial Reporting***

There has been no change in our internal control over financial reporting during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

**PART II - OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company's financial statements.

**ITEM 1A. RISK FACTORS.**

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES**

Below is a list of securities sold by the Company from January 1, 2026, through the date of filing which were not registered under the Securities Act.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Entity** | **Date of Investment** | **Title of Security** | **Amount of**<br> **Securities Sold** | **Consideration** |
| Larry Chimerine | 01/05/26 | Common Stock | 200000 | Purchase @ $0.125 per share |
| Anthony Santelli, Sr. | 01/20/26 | Common Stock | 625000 | Exercise of Warrants |
| Mark Monahan | 02/04/26 | Common Stock | 400000 | Purchase @ $0.125 per share |
| Joe Galbo | 02/10/26 | Common Stock | 10000 | Stock for Services |
| Anthony Santelli, Sr. | 02/24/26 | Common Stock | 625000 | Exercise of Warrants |
| David Bolton | 03/06/26 | Common Stock | 416000 | Purchase @ $0.125 per share |
| Anthony Santelli, Sr. | 03/26/26 | Common Stock | 800000 | Purchase @ $0.125 per share |

---

The securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(a)(2) of that Act and Rules 504 and 506 of Regulation D.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

None.

**ITEM 6. EXHIBITS**

The exhibits listed below are filed as part of or incorporated by reference in this report.

---

| | |
|:---|:---|
| **Exhibit No.** | **Identification of Exhibit** |
| 3.1 | [Articles of Incorporation (incorporated by reference to the Company's S-1 filed May 23, 2012)](https://www.sec.gov/Archives/edgar/data/1549145/000114544312000754/d29479_ex3i.htm) |
| 3.2 | [Certificate of Amendment to Articles of Incorporation filed November 19, 2014](ex3-2.htm) |
| 3.3 | [Certificate of Amendment to Articles of Incorporation filed June 17, 2016 (incorporated by reference to the Company's Form 10-12G/A filed on February 16, 2021)](https://www.sec.gov/Archives/edgar/data/1549145/000149315221004040/ex3-1b.htm) |
| 3.4 | [Certificate of Amendment to Articles of Incorporation filed July 26, 2021 (incorporated by reference to the Company's 8-K filed on July 30, 2021)](https://www.sec.gov/Archives/edgar/data/1549145/000149315221018158/ex3-1.htm) |
| 3.5 | [Bylaws (incorporated by reference to the Company's Form 10-12G/A filed on February 16, 2021)](https://www.sec.gov/Archives/edgar/data/1549145/000149315221004040/ex3-2.htm) |
| 10.1 | [Employment Agreement, dated June 1, 2020, between the Company and Ben Slager (incorporated by reference to the Company's Form 10-12G/A filed on February 16, 2021)](https://www.sec.gov/Archives/edgar/data/1549145/000149315221004040/ex10-b.htm) |
| 10.2 | [Employment Agreement, dated June 1, 2020, between the Company and Anthony Santelli (incorporated by reference to the Company's Form 10-12G/A filed on February 16, 2021](https://www.sec.gov/Archives/edgar/data/1549145/000149315221004040/ex10-c.htm) |
| 10.3 | [2021 Employee, Director Stock Plan (incorporated by reference to definitive 14C filed with the SEC on June 24, 2021)](https://www.sec.gov/Archives/edgar/data/1549145/000149315221015192/formdef14c.htm) |
| 31.1. | [Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-1.htm) |
| 31.2 | [Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex31-2.htm) |
| 32.1 | [Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-1.htm) |
| 32.2 | [Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex32-2.htm) |
| 101.INS | Inline XBRL Instance Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Blue Biofuels, Inc. | Blue Biofuels, Inc. |
| (Registrant) | (Registrant) |
| By | */s/ Benjamin Slager* |
|  | Benjamin Slager |
|  | Chief Executive Officer, (Principal Executive Officer) |
| Date May 4, 2026 | Date May 4, 2026 |
| By | */s/ Anthony Santelli* |
|  | Anthony Santelli |
|  | Chief Financial Officer (Principal Financial and Accounting Officer) |
| Date May 4, 2026 | Date May 4, 2026 |

---

## Exhibit 3.2

**Exhibit 3.2**

![](ex3-2_001.jpg)

![](ex3-2_002.jpg)

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Benjamin Slager, certify that:

1. I have reviewed this quarterly report on Form 10Q of Blue Biofuels, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: May 4, 2026 |
| */s/ Benjamin Slager* |
| Benjamin Slager |
| Chief Executive Officer<br> *(Principal Executive Officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Anthony Santelli, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: May 4, 2026 |
| */s/ Anthony Santelli* |
| Anthony Santelli |
| Chief Financial Officer<br> *(Principal Financial and Accounting Officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Benjamin Slager, the Chief Executive Officer of Blue Biofuels, Inc (the "Company"), DOES HEREBY CERTIFY that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

IN WITNESS WHEREOF, the undersigned has executed this statement this 4<sup>th</sup> day of May, 2026.

---

| |
|:---|
| */s/ Benjamin Slager* |
| Benjamin Slager |
| Chief Executive Officer<br> *(Principal Executive Officer)* |

---

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Anthony Santelli, the Chief Financial Officer of Blue Biofuels, Inc. (the "Company"), DOES HEREBY CERTIFY that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

IN WITNESS WHEREOF, the undersigned has executed this statement this 4<sup>th</sup> day of May, 2026.

---

| |
|:---|
| */s/ Anthony Santelli* |
| Anthony Santelli |
| Chief Financial Officer<br> *(Principal Financial and Accounting Officer)* |

---

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.